L'Institut Curie est un acteur majeur de la recherche et de la lutte contre le cancer. Il est constitué d'un hôpital, et d'un Centre de Recherche de 1100 personnes environ avec une forte représentativité internationale.
L’objectif du Centre de Recherche de l’institut Curie est de développer la recherche fondamentale et d’utiliser les connaissances produites pour améliorer le diagnostic, le pronostic, la thérapeutique des cancers dans le cadre du continuum entre la recherche fondamentale et l’innovation au service du malade.
Main missions of the position
The open position is in line with recent developments and an effort to strengthen the interface between immunology single-cell technologies and bioinformatics. The postdoctoral fellow will be co-supervised by S. Amigorena and Prof. A Griffiths, director of the Laboratory of Biochemistry (LBC) at the ESPCI. The research activities of LBC are based around droplet-based microfluidics, a powerful new ultrahigh-throughput system in which reaction volumes can be miniaturized by up to a million-fold compared to conventional assays in microtiter plates. Both institutes, Curie and ESPCI, are located in the center of Paris, in a both cultural and scientific rich environment.
Project: We are developing a prototype droplet-based microfluidics system for single-cell transcriptomic, epigenetic and phenotypic analysis as well as paired TCR α-β chain sequencing of immune cells.
Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer. Despite the improved patient survival achieved with the advent of immunotherapies, about 60-70% of patients don’t respond to treatment or relapse later on. This underscores the need for understanding the evasion/resistance immune mechanisms within the tumor microenvironment (including myeloid cells and T lymphocytes) that hinder an effective anti-tumor immunity.
This powerful droplet-based microfluidics system will provide unprecedented information on single-cell heterogeneity of tumor-infiltrating immune cells and the complexity of their interactions with other cells within the tumor, thereby paving the way for cancer biomarker and therapeutic target discovery.
The candidate will apply bioinformatics analysis on transcriptomic (scRNA-Seq), epigenetic (scChIP-Seq) and phenotypic (Ab-Seq) data to improve our understanding of the evasion/resistance immune mechanisms within the tumor microenvironment.
This position is supported by DIM ELICIT “Empowering LIfe sCiences with Innovative Technologies” funding.
In close collaboration with wet lab postdocs and students, the candidate will help design experiments and will be in charge of integrating and interpreting comprehensive next generation sequencing datasets:
- Single-cell NSG data (including ChIP-Seq and RNA-Seq)
- Pathways and Enrichment analyses (Networks, Functional, Transcription Factor Binding Sites…).
He/she will benefit from strong interactions within the bioinformatics team in the “Immunity and Cancer” unit headed by Sebastian Amigorena (15 people) and in the LBC/ESPCI headed by Andrew Griffiths (25 people)
The candidate should be an expert in bioinformatics/computational biology or in a relevant biological field with quantitative/computational experience, and a strong interest in immunology. He should ideally have skills in statistics. We expect strong curiosity and motivation to work with and for others.
PhD in bioinformatics/computational biology or in a relevant biological field with quantitative/computational experience